Abstract: Smart gesturing may facilitate smart shopping and other contactless experiences by enabling a user to perform a natural gesture toward one or more desired items with or while wearing a wearable or non-wearable electronic device. The electronic device may identify the smart gesture, and determine the one or more desired items are indicated by the smart gesture. The electronic device may identify the desired items by receiving location data of multiple items, determining a vector based on a first position a second position of the smart gesture, extending the vector to a location, and using the location data to determine which item or items correspond to the location. If more than one item is indicated by the smart gesture, the electronic device may enable selection of the items and, if at least one item is selected, provide information on the selected items or enable additional interaction with the selected items.

Abstract: Smart gesturing may facilitate smart shopping and other contactless experiences by enabling a user to perform a natural gesture toward one or more desired items with or while wearing a wearable or non-wearable electronic device. The electronic device may identify the smart gesture, and determine the one or more desired items are indicated by the smart gesture. The electronic device may identify the desired items by receiving location data of multiple items, determining a vector based on a first position a second position of the smart gesture, extending the vector to a location, and using the location data to determine which item or items correspond to the location. If more than one item is indicated by the smart gesture, the electronic device may enable selection of the items and, if at least one item is selected, provide information on the selected items or enable additional interaction with the selected items.

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: The present invention discloses compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the prophylaxis and/or treatment of cardiovascular disorders and/or dyslipidemia, by administering the compound according to Formula (I).

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: The invention pertains to a projection assembly comprising at least a first screen (14) and a second screen (10). The first screen (14) is at an angle with the second screen (10). The first screen (14) is adapted to reflect light projected onto it predominantly or exclusively in one or more angular ranges that do not intersect with the second screen (10). The invention also pertains to a method for projecting images with such a projection assembly, comprising projecting a first image with the first projector (16B) on the first screen (14), and projecting a second image with the second projector (16A) on the second screen (10).

Abstract: The present invention discloses compounds according to Formula I; or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of inflammatory conditions, by administering the compound according to Formula I.

Abstract: The present invention discloses compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the prophylaxis and/or treatment of cardiovascular disorders and/or dyslipidemia, by administering the compound according to Formula (I).

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: A projection assembly comprising at least a first screen (14) and a second screen (10). The first screen (14) is at an angle with the second screen (10). The first screen (14) is adapted to reflect light projected onto it predominantly or exclusively in one or more angular ranges that do not intersect with the second screen (10). The invention also pertains to a method for projecting images with such a projection assembly, comprising projecting a first image with the first projector (16B) on the first screen (14), and projecting a second image with the second projector (16A) on the second screen (10).

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: The invention pertains to a projection assembly comprising at least a first screen (14) and a second screen (10). The first screen (14) is at an angle with the second screen (10). The first screen (14) is adapted to reflect light projected onto it predominantly or exclusively in one or more angular ranges that do not intersect with the second screen (10). The invention also pertains to a method for projecting images with such a projection assembly, comprising projecting a first image with the first projector (16B) on the first screen (14), and projecting a second image with the second projector (16A) on the second screen (10).

Abstract: A projection assembly comprising at least a first screen (14) and a second screen (10). The first screen (14) is at an angle with the second screen (10). The first screen (14) is adapted to reflect light projected onto it predominantly or exclusively in one or more angular ranges that do not intersect with the second screen (10). The invention also pertains to a method for projecting images with such a projection assembly, comprising projecting a first image with the first projector (16B) on the first screen (14), and projecting a second image with the second projector (16A) on the second screen (10).

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: The present invention relates to a method for compensating ageing effects of pixel outputs displaying an image on a display device. The method involves displaying a first image on an active display area (6) on the display device (1) having a first plurality of pixels; displaying a second image on a sub-area (7) of the display device (1) and having a second plurality of pixels, the active display area (6) being larger than the sub-area (7) and the second image being smaller than the first image and having fewer pixels than the active display area (6); driving the pixels of the sub-area (7) with pixel values that are representative or indicative for the pixels in the activity display area (6); making optical measurements on light emitted from the sub-area (7) and generating optical measurement signals (11) therefrom, and; controlling the display of the image on the active display area (6) in accordance with the optical measurement signals (11) of the sub-area (7).

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.

Abstract: The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate as well as novel intermediates for use in said process. (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate is particularly useful as an HIV protease inhibitor.

Abstract: A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention.